よむ、つかう、まなぶ。
参考資料4 有効性評価に基づく子宮頸がん検診ガイドライン更新版2020年３月31日 (61 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_25869.html |
| 出典情報 | がん検診のあり方に関する検討会（第35回 5／25）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Mandal R, Amin G, Goswami S, Pal S, Patil S, Dhakad N, Frappart L, Fontaniere B.
Accuracy of human papillomavirus testing in primary screening of cervical neoplasia:
results from a multicenter study in India. Int J Cancer. 2004; 112(2): 341-347.
19） Coste J, Cochand-Priollet B, de Cremoux P, Le Galès C, Cartier I, Molinié V, Labbé
S, Vacher-Lavenu MC, Vielh P; French Society of Clinical Cytology Study Group. Cross
sectional study of conventional cervical smear, monolayer cytology, and human
papillomavirus DNA testing for cervical cancer screening. BMJ. 2003; 326(7392): 733.
20） Gray NM, Sharp L, Cotton SC, Masson LF, Little J, Walker LG, Avis M, Philips Z,
Russell I, Whynes D, Cruickshank M, Woolley CM; TOMBOLA group. Psychological
effects of a low-grade abnormal cervical smear test result: anxiety and associated factors.
Br J Cancer. 2006; 94(9): 1253-1262.
21） Thangarajah F, Einzmann T, Bergauer F, Patzke J, Schmidt-Petruschkat S, Theune
M, Engel K, Puppe J, Richters L, Mallmann P, Kirn V. Cervical screening program and
the psychological impact of an abnormal Pap smear: a self-assessment questionnaire
study of 590 patients. Arch Gynecol Obstet. 2016; 293(2): 391-398.
22） McCaffery KJ, Irwig L, Turner R, Chan SF, Macaskill P, Lewicka M, Clarke J,
Weisberg E, Barratt A. Psychosocial outcomes of three triage methods for the
management of borderline abnormal cervical smears: an open randomised trial. BMJ.
2010; 340: b4491.
23 ） Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P. The
psychosocial impact of human papillomavirus testing in primary cervical screening―a
study within a randomized trial. Int J Gynecol Cancer. 2008; 18(4): 743-748.
24） Hendry M, Pasterfield D, Lewis R, Clements A, Damery S, Neal RD, Adke R, Weller
D, Campbell C, Patnick J, Sasieni P, Hurt C, Wilson S, Wilkinson C. Are women ready
for the new cervical screening protocol in England? A systematic review and qualitative
synthesis of views about human papillomavirus testing. Br J Cancer. 2012; 107(2): 243254.
25 ） van Luijt PA, Rozemeijer K, Naber SK, Heijnsdijk EA, van Rosmalen J, van
Ballegooijen M, de Koning HJ. The role of pre-invasive disease in overdiagnosis: a
microsimulation study comparing mass screening for breast cancer and cervical cancer.
J Med Screen. 2016; 23(4): 210-216.
26） Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The
benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;
108(11): 2205-2240.
27） Malila N, Leinonen M, Kotaniemi-Talonen L, Laurila P, Tarkkanen J, Hakama M.
The HPV test has similar sensitivity but more overdiagnosis than the Pap test ―a
Accuracy of human papillomavirus testing in primary screening of cervical neoplasia:
results from a multicenter study in India. Int J Cancer. 2004; 112(2): 341-347.
19） Coste J, Cochand-Priollet B, de Cremoux P, Le Galès C, Cartier I, Molinié V, Labbé
S, Vacher-Lavenu MC, Vielh P; French Society of Clinical Cytology Study Group. Cross
sectional study of conventional cervical smear, monolayer cytology, and human
papillomavirus DNA testing for cervical cancer screening. BMJ. 2003; 326(7392): 733.
20） Gray NM, Sharp L, Cotton SC, Masson LF, Little J, Walker LG, Avis M, Philips Z,
Russell I, Whynes D, Cruickshank M, Woolley CM; TOMBOLA group. Psychological
effects of a low-grade abnormal cervical smear test result: anxiety and associated factors.
Br J Cancer. 2006; 94(9): 1253-1262.
21） Thangarajah F, Einzmann T, Bergauer F, Patzke J, Schmidt-Petruschkat S, Theune
M, Engel K, Puppe J, Richters L, Mallmann P, Kirn V. Cervical screening program and
the psychological impact of an abnormal Pap smear: a self-assessment questionnaire
study of 590 patients. Arch Gynecol Obstet. 2016; 293(2): 391-398.
22） McCaffery KJ, Irwig L, Turner R, Chan SF, Macaskill P, Lewicka M, Clarke J,
Weisberg E, Barratt A. Psychosocial outcomes of three triage methods for the
management of borderline abnormal cervical smears: an open randomised trial. BMJ.
2010; 340: b4491.
23 ） Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P. The
psychosocial impact of human papillomavirus testing in primary cervical screening―a
study within a randomized trial. Int J Gynecol Cancer. 2008; 18(4): 743-748.
24） Hendry M, Pasterfield D, Lewis R, Clements A, Damery S, Neal RD, Adke R, Weller
D, Campbell C, Patnick J, Sasieni P, Hurt C, Wilson S, Wilkinson C. Are women ready
for the new cervical screening protocol in England? A systematic review and qualitative
synthesis of views about human papillomavirus testing. Br J Cancer. 2012; 107(2): 243254.
25 ） van Luijt PA, Rozemeijer K, Naber SK, Heijnsdijk EA, van Rosmalen J, van
Ballegooijen M, de Koning HJ. The role of pre-invasive disease in overdiagnosis: a
microsimulation study comparing mass screening for breast cancer and cervical cancer.
J Med Screen. 2016; 23(4): 210-216.
26） Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The
benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;
108(11): 2205-2240.
27） Malila N, Leinonen M, Kotaniemi-Talonen L, Laurila P, Tarkkanen J, Hakama M.
The HPV test has similar sensitivity but more overdiagnosis than the Pap test ―a